Identification of SLPI (Secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation

Ulla Westin; Åsa Polling; Irena Ljungkrantz; Kjell Ohlsson

doi:10.1515/BC.1999.063

Identification of SLPI (Secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation

Ulla Westin, Åsa Polling, Irena Ljungkrantz, Kjell Ohlsson

Laryngoesophagology, Allergy and Life Quality

Skåne University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

Recently interest has been focused on secretory leucocyte protease inhibitor (SLPI) and its role in immediate hypersensitive reactions, possibly by inhibiting mast cell chymase. The purpose of this investigation was to show whether or not SLPI is produced in mast cells. Double-immunolabelling revealed that SLPI coexists with mast cell tryptase (60%) and chymase (37%). On the other hand, in situ hybridisation studies demonstrated the expression of SLPI mRNA in all mast cells. The differences in results can be attributed to the fact that in situ hybridisation is a more sensitive method than immunohistochemistry. Hence, we conclude that SLPI is produced in human tonsillar mast cells.

Original language	English
Pages (from-to)	489-493
Journal	Biological Chemistry
Volume	380
Issue number	4
DOIs	https://doi.org/10.1515/BC.1999.063
Publication status	Published - 1999 Apr

Keywords

Chymase
Mast cell
Protease inhibitor
SLPI
Tryptase

Access to Document

10.1515/BC.1999.063

Cite this

@article{ae1110d6b7fb4db4ae57172d0fa42091,

title = "Identification of SLPI (Secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation",

abstract = "Recently interest has been focused on secretory leucocyte protease inhibitor (SLPI) and its role in immediate hypersensitive reactions, possibly by inhibiting mast cell chymase. The purpose of this investigation was to show whether or not SLPI is produced in mast cells. Double-immunolabelling revealed that SLPI coexists with mast cell tryptase (60%) and chymase (37%). On the other hand, in situ hybridisation studies demonstrated the expression of SLPI mRNA in all mast cells. The differences in results can be attributed to the fact that in situ hybridisation is a more sensitive method than immunohistochemistry. Hence, we conclude that SLPI is produced in human tonsillar mast cells.",

keywords = "Chymase, Mast cell, Protease inhibitor, SLPI, Tryptase",

author = "Ulla Westin and {\AA}sa Polling and Irena Ljungkrantz and Kjell Ohlsson",

year = "1999",

month = apr,

doi = "10.1515/BC.1999.063",

language = "English",

volume = "380",

pages = "489--493",

journal = "Biological Chemistry",

issn = "1437-4315",

publisher = "De Gruyter",

number = "4",

}

TY - JOUR

T1 - Identification of SLPI (Secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation

AU - Westin, Ulla

AU - Polling, Åsa

AU - Ljungkrantz, Irena

AU - Ohlsson, Kjell

PY - 1999/4

Y1 - 1999/4

N2 - Recently interest has been focused on secretory leucocyte protease inhibitor (SLPI) and its role in immediate hypersensitive reactions, possibly by inhibiting mast cell chymase. The purpose of this investigation was to show whether or not SLPI is produced in mast cells. Double-immunolabelling revealed that SLPI coexists with mast cell tryptase (60%) and chymase (37%). On the other hand, in situ hybridisation studies demonstrated the expression of SLPI mRNA in all mast cells. The differences in results can be attributed to the fact that in situ hybridisation is a more sensitive method than immunohistochemistry. Hence, we conclude that SLPI is produced in human tonsillar mast cells.

AB - Recently interest has been focused on secretory leucocyte protease inhibitor (SLPI) and its role in immediate hypersensitive reactions, possibly by inhibiting mast cell chymase. The purpose of this investigation was to show whether or not SLPI is produced in mast cells. Double-immunolabelling revealed that SLPI coexists with mast cell tryptase (60%) and chymase (37%). On the other hand, in situ hybridisation studies demonstrated the expression of SLPI mRNA in all mast cells. The differences in results can be attributed to the fact that in situ hybridisation is a more sensitive method than immunohistochemistry. Hence, we conclude that SLPI is produced in human tonsillar mast cells.

KW - Chymase

KW - Mast cell

KW - Protease inhibitor

KW - SLPI

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=0032940249&partnerID=8YFLogxK

U2 - 10.1515/BC.1999.063

DO - 10.1515/BC.1999.063

M3 - Article

C2 - 10355635

AN - SCOPUS:0032940249

VL - 380

SP - 489

EP - 493

JO - Biological Chemistry

JF - Biological Chemistry

SN - 1437-4315

IS - 4

ER -

Identification of SLPI (Secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this